Table 2.
Association of HLA-A*31:01, proxy SNP rs1061235 and HLA-B*15:02 with CBZ hypersensitivity.
| Total N | HLA-A*31:01 | rs1061235T | HLA-B*15:02 | Combinedd | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N positive | OR (95% CI) | P-valuea | N positive | OR (95% CI) | P-valuea | N positive | OR (95% CI) | P-valuea | OR (95% CI) | P-valuea | ||
| CBZ-HSS | 6 | 3 (50) | 26.36 (2.53–307.89) | 0.0025 | 4 (66.7) | 25.97 (3.07–340.87) | 8.2×10−4 | - | 4.44 (0.16–120.08)b | 1.000 | 19.05 (1.95–197.65) | 0.0048 |
| CBZ-MPE | 26 | 6 (23.1) | 8.57 (1.67–57.50) | 0.0037 | 9 (34.6) | 7.32 (2.03–28.65) | 7.4×10−4 | - | 1.09 (0.04–27.51)b | 1.000 | 6.09 (1.31–32.25) | 0.0095 |
| CBZ-SJS/TEN | 9 | - | 1.33 (0.06–27.76)b | 1.000 | - | 0.69 (0.04–13.27)b | 1.000 | 3 (33.3) | 38.65 (2.68–2239.5) | 0.0022 | 9.87 (1.18–75.50) | 0.017 |
| CBZ-AGEP | 1 | - | - | - | 1 (100) | - | - | - | - | - | - | - |
| All CBZ cases | 42 | 9 (21.4) | 7.85 (1.82–47.80) | 0.0016 | 14 (33.3) | 6.96 (2.25–24.32) | 1.5×10−4 | 3 (7.1) | 6.51 (0.50–350.5) | 0.101 | 8.14 (2.25–37.34) | 2.6×10−4 |
| HSS/MPE | 32 | 9 (28.1) | 11.18 (2.53–69.27) | 2.6×10−4 | 13 (40.6) | 9.45 (2.91–34.50) | 2.6×10−5 | - | 0.86 (0.03–21.66)b | 1.000 | 7.94 (2.00–38.55) | 8.9×10−5 |
| CBZ-tolerant | 91/87c | 3 (3.3) | - | - | 6 (6.6) | - | - | 1 (1.1) | - | - | - | - |
AGEP, Acute Generalized Exanthematous Pustulosis; CBZ, carbamazepine; CI, confidence interval; HSS, drug-induced hypersensitivity syndrome; MPE, maculopapular exanthem; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis; OR, odds ratio
a
Calculated using Fisher’s exact test
b
Calculated by adding 0.5 to each value in a 2×2 contingency table and using normal approximation.
c
HLA-B*15:02 genotyping failed for four CBZ-tolerant patients
d
Combined analysis of HLA-A*31:01 and HLA-B*15:02
Significant P-values are indicated in bold.